Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

ORION B

ORNBV.HEFI0009014377NASDAQ HelsinkiFIEUR
Stock price
ORION B
Loading chart...

Coverage

Latest articles

U.S. FDA approves new indication for Orion-Bayer prostate cancer drug
8 Jun 2025, 20:27ORNBV.HENASDAQ Helsinki

Filings

Recent filings

FilingDate
*CONVERSION OF A-SHARE INTO B-SHARE: ORI7 Jul 2003
Orion centralises pharmaceutical manufac3 Jul 2003
Oriola Oy to acquire the shares of KD Tu25 Jun 2003
Orion focuses on pharmaceuticals25 Jun 2003
Stalevo, Orion's new treatment for Parki13 Jun 2003
Orion Pharma is focusing R&D5 Jun 2003
Orion Pharma introduces negotiations wit27 May 2003
Orion Group Interim Report 1-3/200313 May 2003
Search

Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).

  • Previous
  • 1
  • 2
  • Next
Orion putting aside the New Venture proj
12 May 2003
B-warrants 1998 of Orion Corporation quo30 Apr 2003
Profit warning: Orion estimates notably14 Apr 2003
Information on the AGM of Orion Corporat28 Mar 2003
  • Previous
  • 1
  • More pages
  • 91
  • 92
  • 93
  • More pages
  • 95
  • Next
Company
ORION B
ORNBV.HENASDAQ Helsinki
Website: Unavailable
Coverage
7
Filings
1,130